---
layout: post
title: "Laser-Assisted In Situ Keratomileusis Lasers-Patient Labeling Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability"
date: 2026-02-05 18:59:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-16166
original_published: 2022-07-28 00:00:00 +0000
significance: 8.00
---

# Laser-Assisted In Situ Keratomileusis Lasers-Patient Labeling Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 28, 2022 00:00 UTC
**Document Number:** 2022-16166

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Laser-Assisted In Situ Keratomileusis (LASIK) Lasers--Patient Labeling Recommendations." This draft guidance recommends content and formatting for patient labeling information for LASIK devices. FDA is issuing this guidance to help ensure that physicians can share and patients can understand information on the benefits and risks of these devices. The recommendations are being made based on concerns that some patients are not receiving and/or understanding information regarding the benefits and risks of LASIK devices. This draft guidance is not final nor is it for implementation at this time.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/28/2022-16166/laser-assisted-in-situ-keratomileusis-lasers-patient-labeling-recommendations-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-16166

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
